Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06394804 · ClinicalTrials.gov registry record · Phase 2
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
A Phase 2 study of Low-Grade Serous Ovarian Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 8
- Study locations
NCT06394804: Recruiting Phase 2 study of Low-Grade Serous Ovarian Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06394804 is a Phase 2 study of Low-Grade Serous Ovarian Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 20 participants. The trial reports 8 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06394804, a Phase 2 study of Low-Grade Serous Ovarian Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 8
- Study locations
Study Summary
The researchers are doing this study to find out whether the combination of avutometinib, defactinib, and letrozole is an effective treatment for people with low-grade serous ovarian cancer (LGSOC). The researchers will also look at the safety of this combination.
Conditions Studied
Interventions
- DRUG Avutometinib
- DRUG Defactinib
- DRUG Letrozole
Study Locations (8)
New York
- Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Georgia
- Emory Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-04-29 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06394804
The ClinicalTrials.gov registry entry for NCT06394804 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Low-Grade Serous Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which Avutometinib is the first listed.
NCT06394804 reports 8 study locations spanning 3 distinct geographic areas - top geographies include New York, New Jersey, Georgia.
Frequently Asked Questions
What is clinical trial NCT06394804 about?
NCT06394804 is a clinical study titled "A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer". The researchers are doing this study to find out whether the combination of avutometinib, defactinib, and letrozole is an effective treatment for people with low-grade serous ovarian cancer (LGSOC). The researchers will also look at the safety of this combination.
What is the current status of trial NCT06394804?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-04-29. Estimated completion is 2027-04.
What conditions does trial NCT06394804 study?
This clinical trial studies the following conditions: Low-Grade Serous Ovarian Cancer.
What interventions are being tested in trial NCT06394804?
The interventions under investigation include: Avutometinib (DRUG), Defactinib (DRUG), Letrozole (DRUG).
Who is sponsoring clinical trial NCT06394804?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06394804 being conducted?
This trial has 8 study locations across Georgia, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low-Grade Serous Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
RECRUITING · Phase 3
-
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.